loader
Please Wait
Applying Filters...

Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Approved Drug Products containing 209241 listed in the FDA Orange Book. Original Data : FDA Website

    Client Virtual Booth
    Menu

    Neurocrine Biosciences

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Send me more info on How To Grow My Business Digitally?

    Left Arrow
    Right Arrow
    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 NEUROCRINE (3)

    filter

    01 CAPSULE;ORAL (3)

    filter

    01 RX (3)

    filter

    01 INGREZZA (3)

    filter

    01 Yes (3)

    ListList of Suppliers
    refresh Reset Filter
    refresh Reset Filter
    product-page Supplier Virtual Booth
    price-trend Ask Us
    Contact Supplier
      Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
      Post an Enquiry Post an Enquiry
      Flag U.S.A
      Virtual Booth Virtual Booth
      Digital Content Digital Content

      VALBENAZINE TOSYLATE

      PDF Supplier PDF
      URL Supplier Web Content
      CAPSULE; ORAL
      EQ 80MG BASE
      2017-10-04
      209241
      INGREZZA
      RX
      Yes
      ASK
      US
      PHARMACOMPASS
      Upload
      your Marketing & Sales content
      Contact Supplier
        Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
        Post an Enquiry Post an Enquiry
        Flag U.S.A
        Virtual Booth Virtual Booth
        Digital Content Digital Content

        VALBENAZINE TOSYLATE

        PDF Supplier PDF
        URL Supplier Web Content
        CAPSULE; ORAL
        EQ 60MG BASE
        2021-04-23
        209241
        INGREZZA
        RX
        Yes
        ASK
        US
        PHARMACOMPASS
        Upload
        your Marketing & Sales content
        Contact Supplier
          Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
          Post an Enquiry Post an Enquiry
          Flag U.S.A
          Virtual Booth Virtual Booth
          Digital Content Digital Content

          VALBENAZINE TOSYLATE

          PDF Supplier PDF
          URL Supplier Web Content
          CAPSULE; ORAL
          EQ 40MG BASE
          2017-04-11
          209241
          INGREZZA
          RX
          Yes
          ASK
          US
          PHARMACOMPASS
          Upload
          your Marketing & Sales content

          Looking for FDA Orange Book APPLICATION 209241

          Looking for FDA Orange Book APPLICATION 209241 3

          19

          Neurocrine Biosciences, based in U.S.A, is a pharmaceutical company.

          One of their notable products is VALBENAZINE TOSYLATE, with a corresponding application number 209241.

          Regulatory Information RX

          With a dosage strength EQ 80MG BASE

          Dosage Form Route CAPSULE; ORAL

          Reference Listed Drug Yes

          Approved since 2017-10-04

          18

          Neurocrine Biosciences, based in U.S.A, is a pharmaceutical company.

          One of their notable products is VALBENAZINE TOSYLATE, with a corresponding application number 209241.

          Regulatory Information RX

          With a dosage strength EQ 60MG BASE

          Dosage Form Route CAPSULE; ORAL

          Reference Listed Drug Yes

          Approved since 2021-04-23

          17

          Neurocrine Biosciences, based in U.S.A, is a pharmaceutical company.

          One of their notable products is VALBENAZINE TOSYLATE, with a corresponding application number 209241.

          Regulatory Information RX

          With a dosage strength EQ 40MG BASE

          Dosage Form Route CAPSULE; ORAL

          Reference Listed Drug Yes

          Approved since 2017-04-11

          Post Enquiry
          POST ENQUIRY